GPT and Thrombocytopenia: T-DM1 was discontinued due to thrombocytopenia (4.2%), elevated blood bilirubin level (2.6%), elevated aspartate aminotransferase level (1.6%), elevated alanine aminotransferase level (1.5%), peripheral sensory neuropathy (1.5%) and decreased ejection fraction (1.2%).